Physician profile
Travis Pickens
NPI 1053346783
$3,493.76
in general payments reported to CMS, 2019-2025
20 companies · $821 in 2025
The $821 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $314 · 2021: $180 · 2022: $192 · 2023: $709 · 2024: $771 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,300.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $686.14 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $531.10 | 2023-2025 | Infuse, Miebo, Xiidra |
| Alcon Vision LLC | $471.98 | 2019-2025 | Hydrus Microstent, Tryptyr, Total30 |
| Oyster Point Pharma, INC. | $275.42 | 2022-2024 | Tyrvaya |
| Harrow Eye, LLC | $237.62 | 2024-2025 | Vevye |
| Coopervision INC. | $175.32 | 2019-2021 | |
| Dompe US, INC. | $159.02 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $140.36 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $133.07 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $127.85 | 2019 | |
| Amgen INC. | $124.46 | 2024 | Tepezza |
| Rxsight INC | $91.67 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Allergan, INC. | $76.50 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $66.04 | 2025 | Syfovre |
| Glaukos Corporation | $51.17 | 2022-2025 | Istent Infinite, Idosetr |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $46.58 | 2020 | |
| Abbvie INC. | $42.80 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $23.69 | 2019 | |
| Aerie Pharmaceuticals, INC. | $18.27 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Pickens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.